Enveric Biosciences (ENVB) Net Cash Flow (2010 - 2026)
Enveric Biosciences (ENVB) posted Net Cash Flow of $246369.0 for Q1 2026, down 72.76% sequentially from $904283.0 in Q4 2025, and down 88.02% YoY from $2.1 million in Q1 2025.
Enveric Biosciences (ENVB) Net Cash Flow (2010 - 2026) Analysis & Trends
Enveric Biosciences has reported Net Cash Flow for 17 years, with the latest figure at $246369.0 in Q1 2026.
- Quarterly Net Cash Flow fell 88.02% year-over-year to $246369.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $627001.0 (up 130.51% YoY) and the FY2025 annual result came in at $2.4 million, up 4761.05% from the prior year.
- Net Cash Flow declined to $246369.0 in Q1 2026 per ENVB's latest filing, from $904283.0 in the prior quarter.
- Over five years, Net Cash Flow peaked at $4.3 million in Q1 2022 and troughed at -$5.1 million in Q1 2023.
- A 5-year average of -$664267.7 and a median of -$848101.0 in 2024 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Net Cash Flow slumped 218.39% in 2023, then soared 324.09% in 2025.
- Over 5 years, Net Cash Flow stood at -$3.5 million in 2022, then jumped by 44.15% to -$1.9 million in 2023, then surged by 56.22% to -$848101.0 in 2024, then soared by 206.62% to $904283.0 in 2025, then sank by 72.76% to $246369.0 in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $246369.0, $904283.0, and $917395.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | 3.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 246,369.00 |
| Mar 31, 2026 | 246,369.00 |
| Dec 31, 2025 | 904,283.00 |
| Dec 31, 2025 | 904,283.00 |
| Sep 30, 2025 | 917,395.00 |
| Sep 30, 2025 | 917,395.00 |
| Jun 30, 2025 | -1.44 Mn |
| Jun 30, 2025 | -1.44 Mn |
| Mar 31, 2025 | 2.06 Mn |
| Mar 31, 2025 | 2.06 Mn |
| Dec 31, 2024 | -848,101.00 |
| Dec 31, 2024 | -848,101.00 |
| Sep 30, 2024 | -409,383.00 |
| Sep 30, 2024 | -409,383.00 |
| Jun 30, 2024 | -2.85 Mn |
| Jun 30, 2024 | -2.85 Mn |
| Mar 31, 2024 | 4.06 Mn |
| Mar 31, 2024 | 4.06 Mn |
| Dec 31, 2023 | -1.94 Mn |
| Dec 31, 2023 | -1.94 Mn |